Centre du Cancer Lausanne - Publications 2002




Home < Centre de recherche < Publications 2010 < Publications 2002

Publications 2010

Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

Publications 2004

Publications 2003

	Publications 2002

Publications 2001

Info.onco@chuv.ch

Publications : 2002
1:	Bakr M., N. Ketterer, S. Leyvraz, J. Bauer
		High-dose chemotherapy and autologous blood test stem cell support in male patients with germ-cell tumors. Société Suisse de Médecine interne, 25-27.4.2002, Genève
2:	Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al.
		Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20(7):1759-66.
3:	Delbaldo C, Faivre S, Monnerat C,
		Le Chevalier T. [New drugs in bronchial cancer]. Presse Med 2002;31(17):802-9.
4:	Dormond O, Bezzi M, Mariotti A, Ruegg C.
		Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002;277(48):45838-46.
5:	Dormond O, Lejeune FJ, Ruegg C.
		Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and p27Kip1 expression in endothelial cells by TNF/IFN gamma. Anticancer Res 2002;22(6A):3159-63.
6:	Dutoit V, Rubio-Godoy V, Doucey MA, Batard P, Lienard D, Rimoldi D, et al.
		Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol 2002;168(3):1167-71.
7:	Eggermont AM, Keilholz U, Autier P, Ruiter DJ, Lehmann F, Lienard D.
		The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38 Suppl 4:S114-9.
8:	Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, et al.
		Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002;13(9):1479-89.
9:	Freymond D, Guignet R, Lhote P, Passaquin AC, Ruegg UT.
		Calcium homeostasis and glucose uptake of murine myotubes exposed to insulin, caffeine and 4-chloro-m-cresol. Acta Physiol Scand 2002;176(4):283-92.
10:	Givel JC, Aellen S, Moubayed H, Michetti P, Dorta G, Popescu R.
		Colorectal cancer: curative treatment and surveillance. Rev Med Suisse Romande 2002;122(9):417-9.
11:	Guggisberg D, Cerottini JP, Krischer J, Braun R, Dietrich PY, Lienard D.
		Recommendations for the management of melanoma. Rev Med Suisse Romande 2002;122(1):5-8.
12:	International Breast Cancer Study Group (IBCSG) (Lausanne : S. Levyraz)
		Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer : a randomized trial. J. Natl Cancer Inst. 94, 14 : 1054-1065, 2002.
13:	Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendorf D, et al.
		Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002;38(11):1501-11.
14:	Lejeune FJ, Liénard D.
		Who should we consider for isolated limb perfusion? Newton Bischop J, A., Gore M, editors. Melanoma: critical debates. Oxford: Blackwell Science; 2002. p. 230-237.
15:	Lejeune FJ.
		Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002;110(4):433-5.
16:	Lejeune FJ.
		The impact of surgery on the course of melanoma. Recent Results Cancer Res 2002;160:151-7.
17:	Monnerat C, Bresssac-De Paillerets B, Demenais F.
		Interactions entre gènes : L’exemple du mélanome familial. Lettr Cancerol, 11, 2 : 58-60, 2002.
18:	Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E.
		End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13(7):995-1006.
19:	Monnerat C.
		Carcinogenèse – Quelle est la part des facteurs héréditaires ? Lettr Cancerol, 11, 1, 2002.
20:	Monnerat C.
		Chimioprévention et oncogénétique – Extraits de la 2è conference de Saint-Gall. Lettr Cancerol, 10, 4, 2002.
21:	Morant R, Hsu Schmitz SF, Bernhard J, Thurlimann B, Borner M, Wernli M, et al.
		Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. Eur J Cancer 2002;38(12):1626-32.
22:	Moubayed H, Popescu R, Aellen S, Givel JC, Michetti P, Dorta G.
		Detection and prevention of colorectal cancer Rev Med Suisse Romande 2002;122(9):413-6.
23:	Oosterman S, Decosterd LA, Buclin T, Stupp R, Leyvraz S, Csajka C.
		Population pharmacokinetic of Temozolomide (TMZ) in plasma and CSF in malignant glioma patients. Journée d'interaction des groupes de recherche des facultés de médecine de Genève et Lausanne, Changins 10.10.2002
24:	Peters R, Leyvraz S, Faes-Van't Hull E, Jaunin P, Gerber S, Rollini P.
		Long-term ex vivo expansion of human fetal liver primitive haematopoietic progenitor cells in stroma-free cultures. Br J Haematol 2002;119(3):792-802.
25:	Rüegg C.
		Targeting the tumor vasculature as an anti-cancer therapy : emerging paradigms and open questions. Swiss Medical Forum, 14 : 317-323, 2002.
26:	Raymond E, Campone M, Stupp R, Menten J, Chollet P, Lesimple T, et al.
		Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 2002;38(10):1348-50.
27:	Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, et al.
		Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81-96.
28:	Rosti G, Ferrante P, Ledermann J, Leyvraz S, Ladenstein R, Koscileniak E, et al.
		High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 2002;41(2):129-40.
29:	Ruegg C, Dormond O, Foletti A.
		Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium 2002;9(3):151-60.
30:	Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, et al.
		Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 2002;13(7):1140-50.
31:	Speiser DE, Lienard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, et al.
		In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32(3):731-41.
32:	Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al.
		Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20(5):1375-82.
33:	Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, et al.
		Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002;168(8):4231-40.
34:	Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, et al.
		Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62(6):1743-50.
35:	Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, et al.
		Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002;195(4):485-94.
36:	Zouhair A, Weber D, Belkacemi Y, Ketterer N, Dietrich PY, Villa S, et al.
		Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2002;52(3):652-6.

Dernière modification le 10.06.2008